| Value | ₹200.0 Cr |
|---|
BSE filing, NSE: KPL. Summary written from the filing by ALFA Finder's alert engine.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,473.55
- Market cap
- ₹3,604 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 44.5×Sector 45.9×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Other credit rating announcements
All →Texmaco Rail & Engineering Credit Rating
Crisil Ratings assigned Texmaco Rail & Engineering a long-term bank facilities rating of Crisil A+/Stable. The rating is disclosed under Regulation 30.
Oriana Power Credit Rating
CRISIL reaffirmed Oriana Power's ratings, with long-term CRISIL A-/Stable and short-term CRISIL A2+ on ₹950 Crore of bank facilities. The ₹75 Crore and ₹200 Crore NCDs are also reaffirmed at A-/Stable.
Unifinz Capital India Credit Rating
Crisil assigned BBB-/Stable to Unifinz's Rs.100 crore NCDs and reaffirmed ratings on existing debt. Outlook is stable, with the cyber fraud incident not expected to be material.
Supra Pacific Financial Services Credit Rating
Acuité assigned ACUITE BBB-/Stable to Supra Pacific Financial's bank loan facilities. The rating letter is dated 30 October 2026.
Apollo Pipes Credit Rating
Apollo Pipes Limited's bank facilities worth Rs. 150 Crore were upgraded by ICRA to [ICRA]AA-(Stable)/[ICRA]A1+ from A+. The rationale cites deeper integration with the APL Apollo Group.
Ashoka Buildcon Credit Rating
ICRA reaffirmed and then withdrew Ashoka Buildcon's short-term debt rating of [ICRA] A1+ at the company's request. Other debt instruments remain rated by other agencies.